NASDAQ:CYTK
Cytokinetics Stock News
$71.41
+0.260 (+0.365%)
At Close: Mar 27, 2024
Mizuho: these two biotech stocks are worth buying right now
04:35pm, Monday, 09'th May 2022
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q1 2022 Results - Earnings Call Transcript
10:15pm, Wednesday, 04'th May 2022
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communications and IR Robert Blum - President and
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
06:48pm, Wednesday, 04'th May 2022
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
08:11am, Monday, 02'nd May 2022 Zacks Investment Research
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
05:16am, Monday, 02'nd May 2022
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th
Cytokinetics to Announce First Quarter Results on May 4, 2022
04:00pm, Wednesday, 20'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM
Cytokinetics: A Brighter Future In Muscle Biology
03:59pm, Monday, 11'th Apr 2022
Cytokinetics had a down year in 2019. They have since bounced back to deliver record-high revenues in 2021.
Cytokinetics Announces Changes to Board of Directors
11:30am, Friday, 08'th Apr 2022 GlobeNewswire Inc.
L. Patrick Gage, Ph.D. to Retire from Board
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
08:00pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
01:45pm, Sunday, 03'rd Apr 2022 GlobeNewswire Inc.
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
03:30pm, Saturday, 02'nd Apr 2022 GlobeNewswire Inc.
Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Disopyramide Aficamten Reduced LVOT Gradients and Improved
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2022 it granted stock options to purchase an aggregate of
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
08:00pm, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scienti